where to from here?, page-4

The possibility of a share price rise is lessened by the overall negativity towards the biotech sector. I've been invested in four biotechs over the last year and even though they are all progressing (or regressing) differently, they have all drifted down. I'd like to see at least 15 cents, but it will probably spike and then settle back. While the results, if good, are wonderful for the disease sufferers, in terms of financial outcomes the market might consider it, as a 'rare' disease, too small a segment to bring in the big $$$ and my sentiment is that it might not bring huge results to us as investors. However if they get good results with concussions for example, that could be a major price trigger point.